Classification of scaffold-hopping approaches

Boehm, 2004, Scaffold hopping, Drug Discov. Today: Technol., 1, 217, 10.1016/j.ddtec.2004.10.009

Sneader, 1996

Martin, 2009, Beyond QSAR: lead hopping to different structures, QSAR Comb. Sci., 28, 797, 10.1002/qsar.200810176

Cramer, 2004, ‘Lead hopping’. Validation of topomer similarity as a superior predictor of similar biological activities, J. Med. Chem., 47, 6777, 10.1021/jm049501b

Schneider, 2006, Scaffold-hopping: how far can you jump?, QSAR Comb. Sci., 25, 1162, 10.1002/qsar.200610091

Cramer, 1999, Prospective identification of biologically active structures by topomer shape similarity searching, J. Med. Chem., 42, 3919, 10.1021/jm990159q

Schneider, 1999, ‘Scaffold-Hopping’ by topological pharmacophore search: a contribution to virtual screening, Angew. Chem. Int. Ed., 38, 2894, 10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.0.CO;2-F

Brown, 2006, On scaffolds and hopping in medicinal chemistry, Mini Rev. Med. Chem., 6, 1217, 10.2174/138955706778742768

Jenkins, 2004, A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes, J. Med. Chem., 47, 6144, 10.1021/jm049654z

Stiefl, 2006, ErG: 2D pharmacophore descriptions for scaffold hopping, J. Chem. Inf. Model., 46, 208, 10.1021/ci050457y

Bohl, 2006, Unsupervised 3D ring template searching as an ideas generator for scaffold hopping: use of the LAMDA, RigFit, and field-based similarity search (FBSS) methods, J. Chem. Inf. Model., 46, 1882, 10.1021/ci049657k

Gardiner, 2011, Effectiveness of 2D fingerprints for scaffold hopping, Future Med. Chem., 3, 405, 10.4155/fmc.11.4

Brown, 2010, Bioisosteric replacement and scaffold hopping in lead generation and optimization, Mol. Inform., 29, 366, 10.1002/minf.201000019

Renner, 2006, Scaffold-hopping potential of ligand-based similarity concepts, ChemMedChem, 1, 181, 10.1002/cmdc.200500005

Zhang, 2006, Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring, J. Med. Chem., 49, 1536, 10.1021/jm050468i

Martin, 2002, Do structurally similar molecules have similar biological activity?, J. Med. Chem., 45, 4350, 10.1021/jm020155c

Wassermann, 2010, Chemical substitutions that introduce activity cliffs across different compound classes and biological targets, J. Chem. Inf. Model., 50, 1248, 10.1021/ci1001845

Labute, 2001, Flexible alignment of small molecules, J. Med. Chem., 44, 1483, 10.1021/jm0002634

White, 1988, Behavioural effects of histamine and its antagonists: a review, Psychopharmacology (Berl.), 95, 1, 10.1007/BF00212757

Soter, 1990, Urticaria: current therapy, J. Allergy Clin. Immunol., 86, 1009, 10.1016/S0091-6749(05)80245-3

Piwinski, 1991, Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines, J. Med. Chem., 34, 457, 10.1021/jm00105a069

Southall, 2006, Kinase patent space visualization using chemical replacements, J. Med. Chem., 49, 2103, 10.1021/jm051201m

FitzGerald, 2003, COX-2 and beyond: approaches to prostaglandin inhibition in human disease, Nat. Rev. Drug Discov., 2, 879, 10.1038/nrd1225

Bostroem, 2007, Scaffold hopping, synthesis and structure–activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists, Bioorg. Med. Chem., 15, 4077, 10.1016/j.bmc.2007.03.075

Berggren, 2004

Berggren, 2004, Vol. WO2004058249

Ritchie, 2009, The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?, Drug Discov. Today, 14, 1011, 10.1016/j.drudis.2009.07.014

Ishikawa, 2011, Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry, J. Med. Chem., 54, 1539, 10.1021/jm101356p

Sun, 2004, A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption, J. Chem. Inf. Comput. Sci., 44, 748, 10.1021/ci030304f

Rimon, 2010, Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1, Proc. Natl Acad. Sci. U. S. A., 107, 28, 10.1073/pnas.0909765106

Wang, 2010, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life, Bioorg. Med. Chem. Lett., 20, 7159, 10.1016/j.bmcl.2010.07.054

Walker, 2001, A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors, Biochem. J., 357, 709, 10.1042/0264-6021:3570709

Beno, 2010, MORPH: a new tool for ligand design, J. Chem. Inf. Model., 50, 1159, 10.1021/ci9004964

Pitt, 2009, Heteroaromatic rings of the future, J. Med. Chem., 52, 2952, 10.1021/jm801513z

Lee, 2001, Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries, J. Comb. Chem., 3, 284, 10.1021/cc000097l

Maass, 2007, Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations, J. Chem. Inf. Model., 47, 390, 10.1021/ci060094h

Vieth, 2004, Characteristic physical properties and structural fragments of marketed oral drugs, J. Med. Chem., 47, 224, 10.1021/jm030267j

Hall, 2008, Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping, Bioorg. Med. Chem. Lett., 18, 2684, 10.1016/j.bmcl.2008.03.018

Evelyn, 2010, Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423, Bioorg. Med. Chem. Lett., 20, 665, 10.1016/j.bmcl.2009.11.056

Hodge, 1993, A diazine heterocyclic replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett., 3, 1605, 10.1016/S0960-894X(00)80026-8

Eastwood, 2010, Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement, Bioorg. Med. Chem. Lett., 20, 1634, 10.1016/j.bmcl.2010.01.077

Tasler, 2009, N-substituted 2′-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping, Bioorg. Med. Chem. Lett., 19, 1349, 10.1016/j.bmcl.2009.01.054

Lovering, 2009, Escape from flatland: increasing saturation as an approach to improving clinical success, J. Med. Chem., 52, 6752, 10.1021/jm901241e

Reid, 2004, Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries, J. Med. Chem., 47, 1641, 10.1021/jm030337m

Venkatraman, 2005, Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design, J. Med. Chem., 48, 5088, 10.1021/jm0489556

Uto, 2010, Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trif luoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine], Bioorg. Med. Chem. Lett., 20, 746, 10.1016/j.bmcl.2009.11.043

Allen, 2004, Research applications of the Cambridge Structural Database (CSD), Chem. Soc. Rev., 33, 463, 10.1039/b309040j

Adessi, 2002, Converting a peptide into a drug: strategies to improve stability and bioavailability, Curr. Med. Chem., 9, 963, 10.2174/0929867024606731

Sun, 2004, A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides, Bioorg. Med. Chem., 12, 2671, 10.1016/j.bmc.2004.03.017

Fry, 2006, Utilizing peptide structures as keys for unlocking challenging targets, Mini Rev. Med. Chem., 6, 979, 10.2174/138955706778195171

Vassilev, 2007, MDM2 inhibitors for cancer therapy, Trends Mol. Med., 13, 23, 10.1016/j.molmed.2006.11.002

Vassilev, 2005, p53 Activation by small molecules: application in oncology, J. Med. Chem., 48, 4491, 10.1021/jm058174k

Chai, 2000, Structural and biochemical basis of apoptotic activation by Smac/DIABLO, Nature, 406, 855, 10.1038/35022514

Oosterom, 1999, Conformation of the core sequence in melanocortin peptides directs selectivity for the melanocortin MC3 and MC4 receptors, J. Biol. Chem., 274, 16853, 10.1074/jbc.274.24.16853

Orner, 2001, Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix, J. Am. Chem. Soc., 123, 5382, 10.1021/ja0025548

Sebhat, 2002, Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist, J. Med. Chem., 45, 4589, 10.1021/jm025539h

Vagner, 2008, Peptidomimetics, a synthetic tool of drug discovery, Curr. Opin. Chem. Biol., 12, 292, 10.1016/j.cbpa.2008.03.009

Charriaut-Marlangue, 2004, Apoptosis: a target for neuroprotection, Therapie, 59, 185, 10.2515/therapie:2004035

Fleischer, 2006, Modulating apoptosis as a target for effective therapy, Mol. Immunol., 43, 1065, 10.1016/j.molimm.2005.07.013

Yue, 1999, Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases, Curr. Opin. Chem. Biol., 3, 474, 10.1016/S1367-5931(99)80069-6

Cohen, 2009, Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold, J. Med. Chem., 52, 1723, 10.1021/jm801450c

Vucic, 2005, Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP, Biochem. J., 385, 11, 10.1042/BJ20041108

Lawandi, 2009, Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors, J. Med. Chem., 52, 6672, 10.1021/jm901013a

Kaschina, 2003, Angiotensin AT1/AT2 receptors: regulation, signalling and function, Blood Press., 12, 70, 10.1080/08037050310001057

de Gasparo, 2000, International union of pharmacology. XXIII. The angiotensin II receptors, Pharmacol. Rev., 52, 415

Garcia, 1992, Three-dimensional structure of an angiotensin II-Fab complex at 3A: hormone recognition by an anti-idiotypic antibody, Science, 257, 502, 10.1126/science.1636085

Nikiforovich, 1994, Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation, Biochemistry, 33, 3591, 10.1021/bi00178a016

Rosenstrom, 2004, A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4–5 of angiotensin II, J. Med. Chem., 47, 859, 10.1021/jm030921v

Schmidt, 1997, Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3–5, J. Med. Chem., 40, 903, 10.1021/jm960553d

Rosenstrom, 2006, Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors, J. Med. Chem., 49, 6133, 10.1021/jm051222g

Sanudo, 2009, Synthesis of benzodiazepine beta-turn mimetics by an Ugi 4CC/Staudinger/aza-Wittig sequence. Solving the conformational behavior of the Ugi 4CC adducts, J. Org. Chem., 74, 2189, 10.1021/jo8025862

Georgsson, 2005, Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity, J. Med. Chem., 48, 6620, 10.1021/jm050280z

http://www.chemcomp.com/ (accessed October 2011)

http://accelrys.com/ (accessed October 2011)

http://www.schrodinger.com/ (accessed October 2011)

Sun, 2007, Molecular modeling of melanocortin receptors, Curr. Top. Med. Chem., 7, 1042, 10.2174/156802607780906573

Franke, 2007, Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening, J. Med. Chem., 50, 2640, 10.1021/jm060655w

Lutkenhaus, 1997, Bacterial cell division and the Z ring, Annu. Rev. Biochem., 66, 93, 10.1146/annurev.biochem.66.1.93

Rush, 2005, A shape-based 3-D scaffold hopping method and its application to a bacterial protein–protein interaction, J. Med. Chem., 48, 1489, 10.1021/jm040163o

Sun, 2010, De novo design of potent BCL-xl inhibitors by scaffold hopping and data mining

Lee, 2007, Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family, Cell Death Differ., 14, 1711, 10.1038/sj.cdd.4402178

Fontaine, 2009, SHOP: a method for structure-based fragment and scaffold hopping, ChemMedChem, 4, 427, 10.1002/cmdc.200800355

Bergmann, 2007, SHOP: scaffold HOPping by GRID-based similarity searches, J. Med. Chem., 50, 2708, 10.1021/jm061259g

Kuehn, 2009, NIH program to boost pipeline for drugs to treat rare and neglected diseases, JAMA, 302, 133, 10.1001/jama.2009.940

Irwin, 2005, ZINC – a free database of commercially available compounds for virtual screening, J. Chem. Inf. Model., 45, 177, 10.1021/ci049714+

Chen, 2009, PubChem as a source of polypharmacology, J. Chem. Inf. Model., 49, 2044, 10.1021/ci9001876

Chen, 2010, PubChem BioAssays as a data source for predictive models, J. Mol. Graph. Model., 28, 420, 10.1016/j.jmgm.2009.10.001

Wang, 2010, An overview of the PubChem BioAssay resource, Nucleic Acids Res., 38, D255, 10.1093/nar/gkp965

Wishart, 2006, DrugBank: a comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res., 34, D668, 10.1093/nar/gkj067

Liu, 2007, BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities, Nucleic Acids Res., 35, D198, 10.1093/nar/gkl999

Gaulton, 2011

Huang, 2011, The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics, Sci. Transl. Med., 3, 10.1126/scitranslmed.3001862

Inglese, 2006, Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries, Proc. Natl Acad. Sci. U. S. A., 103, 11473, 10.1073/pnas.0604348103

Bergmann, 2009, SHOP: receptor-based scaffold HOPping by GRID-based similarity searches, J. Chem. Inf. Model., 49, 658, 10.1021/ci800391v